Hi Tigers,
IMO, the numbers mean a LOT. The extension was required to review the impact demonitisation has had on the business short term and also as a means to review the long term prospects of the business. The NOV tie up is just one positive tick that has materialised since the company announced the option extension granted by CX Partners on the 14/02/17. Also of note is that the NOV tie up took less than the 120 days. Another positive step for the longer term prospects of the business imo. Another item that fell into place shortly after was the new appointment of the CEO on 02/03/17. Have another careful review of those RBI stats, but not just for December, January and February but prior to when policy changes took place in November last year. They're not quite at those October 2016 levels yet, but are improving. March-May stats will be telling.
Tony
Return to Normal by March, page-80
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VOR (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online